MedTrace Logo

A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies

NCT06971523 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2025-05-14

No results posted yet for this study

Summary

The primary objective of Phase I of this study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of CTS3497 in patients with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deficient solid tumors and lymphomas.

The primary objective of Phase II of this study is to evaluate the efficacy of CTS3497 in patients with metastatic or locally advanced MTAP-deficient solid tumors and lymphomas.

Conditions

Interventions

DRUG

CTS3497

CTS3497: Orally via capsules

Sponsors & Collaborators

  • CytosinLab Therapeutics Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Haiping Wu, PhD · CytosinLab Therapeutics Co., Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-25
Primary Completion
2028-12-31
Completion
2029-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06971523 on ClinicalTrials.gov